Spark Therapeutics Inc. (ONCE)

43.52
NASDAQ : Health Technology
Prev Close 43.52
Day Low/High 0.00 / 0.00
52 Wk Low/High 34.53 / 96.59
Avg Volume 590.50K
Exchange NASDAQ
Shares Outstanding 37.22M
Market Cap 1.59B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

We May Be Back to Maximum Overbought by Thursday

Breadth has a small window to improve from the poor and lagging action we saw last week.

Spark Therapeutics Reaches Analyst Target Price

In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $64.73, changing hands for $64.82/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program

Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program

Second milestone achieved under 2014 global license agreement with Pfizer

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.

Spark Therapeutics Announces Collaboration With Leading Gene Therapy Center At University Of Massachusetts Medical School

Spark Therapeutics Announces Collaboration With Leading Gene Therapy Center At University Of Massachusetts Medical School

Multi-year collaboration focuses on selecting adeno-associated virus vectors to target debilitating genetic diseases in cells of the retina, liver and central nervous system

Spark Therapeutics Launches Initiative To Improve Access To Genetic Testing For Inherited Retinal Diseases

Spark Therapeutics Launches Initiative To Improve Access To Genetic Testing For Inherited Retinal Diseases

Free Genetic Test Helps Eligible Patients in U.S. Affected by Certain Progressive Retinal Diseases Get Support and Information

Jim Cramer's Top Takeaways: Spark Therapeutics, General Mills, Kellogg, ConAgra, Campbell

Jim Cramer's Top Takeaways: Spark Therapeutics, General Mills, Kellogg, ConAgra, Campbell

Cramer says be prepared to sell the food group because it is getting too difficult to gauge.

Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind

Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind

When the market decides only one thing is working, that makes things treacherous for everyone else,

TheStreet Quant Rating: D (Sell)